University of Turku, Finland Institute of Biomedicine
Phd in Interdisciplinary Medical Sciences (2011) and habilitation in Molecular Genetics (2015).
Professional experience is ranging from early phase research until clinical application published in leading international scientific journals (Cell, Nature Genetics, Clinical Cancer Research) and patented.
Research interest is focused on precision medicine and pharmacogenomics of cancer, with the main line and mission to enable prostate cancer treatment and new drug discovery via innovative genomic biomarkers.
Interested how artificial intelligence and machine learning will transform healthcare. Additional activities as HORIZON2020, Innovative Medicines Initiative (IMI) expert, advisor, editor in scientific journal.
Member: European Society of Pharmacogenomics and Personalised Therapy (ESPT Board)
European Society of Human Genetics (ESHG)
Finnish Society of Clinical Genetics (FSCG)
Finnish Society of Clinical Pharmacology (FSCP)
Turku Cancer Research Society (TCRS Board)